Golimumab is under clinical development by Johnson & Johnson and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes (Juvenile Diabetes) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Golimumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Golimumab (Simponi) is a human monoclonal antibody, acts as immunosuppressant and anti-rheumatic agent. It is formulated as a solution for subcutaneous administration. Simponi in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis, Simponi alone or in combination with methotrexate, is indicated for the treatment of adult patients with active psoriatic arthritis, for the treatment of adult patients with active ankylosing spondylitis, in adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine, for the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).
Simponi (Golimumab) is under development for the treatment of ulcerative colitis and type 1 diabetes. It was also under development for the treatment of musculoskeletal disorders, sarcoidosis, systemic idiopathic juvenile arthritis, structural damage, asthma, posterior uveitis and anterior uveitis.
Johnson & Johnson overview
Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.
For a complete picture of Golimumab’s drug-specific PTSR and LoA scores, buy the report here.